New development of lipid-lowering therapy of coronary heart disease: Bempedoic acid
10.12092/j.issn.1009-2501.2022.04.003
- Author:
Qi WANG
1
;
Yunzeng ZOU
2
Author Information
1. Department of General Medicine, Zhongshan Hospital of Fudan University
2. Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Diseases
- Publication Type:Journal Article
- Keywords:
Bempedoic acid;
Coronary heart disease;
Lipid-lowering therapy;
The new development
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2022;27(4):369-372
- CountryChina
- Language:Chinese
-
Abstract:
Inability to tolerate statins because of muscle symptoms contributes to uncontrolled cholesterol levels and insufficient cardiovascular risk reduction. Bempedoic acid, an enzyme with high expression in the liver but that is undetectable in the skeletal muscle. Lack of the activating enzyme in skeletal muscle may prevent the muscular adverse effects associated with statins. In this review, we summarize the latest advances in bempedoic acid, and review the phase 2 and phase 3 clinical trials results, adverse events, and the clinical trials results in progress of Bempedoic acid. Finally, we discuss the current status of bempedoic acid in the clinical works.
